TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05462236
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD-1 Inhibitor
Study: NCT05462236
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topoisomerase inhibitor
Study: NCT02567175
Drug: Domperidone
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04877990
Drug: Deucravacitinib
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05163106
Drug: Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given letrozole 2.5mg and ribociclib 600mg daily, per oral for a period of 21 days followed by 7 days of letrozole only.
Study: NCT05163106
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premenopausal women will be given goserelin 3.6 mg (subcutaneous) every 4 weeks in concert with their Letrozole and Ribociclib treatment.
Study: NCT06473116
Drug: Isoprenaline Only Product
Normalized name: Isoprenaline only product
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of intravenous isoprenaline of 600 mikrograms immediately after recognition of asystole in bystander-witnessed out-of-hospital cardiac arrest
Study: NCT04824937
Drug: Telaglenastat
Normalized name: Telaglenastat
DrugBank: Telaglenastat (DB15232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, taken by mouth
Study: NCT04824937
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, taken by mouth
Study: NCT06488898
Drug: Allogeneic adipose tissue-derived mesenchymal stem cells
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational medicinal product: Allogeneic adipose tissue-derived mesenchymal stem cells and expanded, which are considered an advanced therapy medicinal product under European regulation (Article 2(1) of Regulation (EC) No 1394/2007 of the European Parliament and the Council of November 13 th 2007 about advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004).~Administration form: Local injection by means of a catheter placed inside the previously excluded aneurysmal sac.~Administration dose: 1x10000000 cells/kg patient weight.~Administration guidelines: single infusion on the endovascular day AAA intervention.
Study: NCT05127122
Drug: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable
Study: NCT00002168
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002168
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002168
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002168
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002168
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04369547
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast 250mcg
Study: NCT05850702
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inhale 5ml of 2% lidocaine by nebulization
Study: NCT05850702
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inhale 5ml of saline by nebulization
Study: NCT05639218
Drug: Inclisiran
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients are receiving PCSK9 inhibitors or inclisiran in the context of optimal hypolipidemic pharmacotherapy
Study: NCT05100303
Drug: Mitoxantrone Hydrochloride liposome injection
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone hydrochloride liposome will be administered by intravenous (IV) injections.
Study: NCT05100303
Drug: Cytarabine (LoDAC)
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose or high-dose cytarabine (LoDAC) will be administered by intravenous (IV) injections.
Study: NCT04408664
Drug: Sodium Cromoglycate
Normalized name: Sodium cromoglycate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Cromoglicate 10 mg/mL packed in ampulla of 2 mL; Daily dosis of 4X20 mg milligram delivered by aerosol.
Study: NCT05498597
Drug: AMT-151
Normalized name: Amtagvi
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT00992654
Drug: Open Label Treatment Access: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dosing twice daily. The dose will depend on the optimized background therapy.
Study: NCT04714190
Drug: RC48-ADC
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg/kg IV every 2 weeks
Study: NCT04714190
Drug: Paclitaxel injection
Normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study: NCT04714190
Drug: Irinotecan Hydrochloride Injection
Normalized name: Irinotecan Hydrochloride Injection
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study: NCT04714190
Drug: Apatinib Mesylate Tablets
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study: NCT03968913
Drug: Anakinra injection
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: anakinra 150mg in 5milliliters of sterile saline will be injected into the knee joint
Study: NCT04668209
Drug: Silmitasertib
Normalized name: Silmitasertib
DrugBank: Silmitasertib (DB15408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care / best supportive care in combination with CX-4945 1000 mg administered orally, two times a day.
Study: NCT05951361
Drug: 0.1% topical triamcinolone Acetonide preparation Kenacourt-A Orabase
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: three times daily for 4 weeks
Study: NCT02953496
Drug: vonapanitase
Normalized name: Vonapanitase
DrugBank: Vonapanitase (DB11690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonapanitase will be administered to the target lesion of the SFA or PA via percutaneous needle injection under ultrasound guidance.
Study: NCT06452602
Drug: Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction immunochemotherapy:~Nab-paclitaxel：220mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Adebrelimab：1200mg, IV，d1, d22.~Evaluation of the Curative Effect：CR+PR~Adebrelimab plus concurrent chemoradiotherapy:~Adebrelimab：1200mg, IV，q3w, until PD; Nab-paclitaxel：175mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Radiotherapy：50.4Gy/1.8Gy/28f.
Study: NCT01351090
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg Intranasal (2 x 100 uL of a 5% solution)
Study: NCT01351090
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg Intranasal (2 x 100 uL of a 15% solution)
Study: NCT00002182
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06300099
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone as adjunct to serratus anterior plane block.
Study: NCT06300099
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine as adjunct to serratus anterior plane block.
Study: NCT05419297
Drug: Buprenorphine Buccal Film [Belbuca]
Normalized name: buprenorphine Buccal Film [Belbuca]
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: buprenorphine buccal film is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Study: NCT05335655
Drug: Dexmedetomidine injection
Normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV initial bolus and trans operative dexmedetomidine infusion.
Study: NCT05335655
Drug: Sodium Chloride 0.9% infusion
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV initial bolus and trans operative infusion of 0.9% saline solution.
Study: NCT00089518
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05971758
Drug: Fimepinostat
Normalized name: Fimepinostat
DrugBank: Fimepinostat (DB11891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will allow us to determine the efficacy and safety of these doses in the treatment of Cushing Disease (CD) and guide dose selection for subsequent, larger studies.
Study: NCT06101147
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: These patients will receive Vitamin D3 1000 I.U daily and the Metformin as prescribed by the physician for 8 weeks.
Study: NCT04871152
Drug: OnabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: To compare the effectiveness of triptans before and after initiation of treatment with OnabotuliumtoxinA.
Study: NCT00939926
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05141071
Drug: Ivabradine 5mg Tab
Normalized name: IVABRADINE 5MG TAB
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ivabradine will be administrated enterally
Study: NCT05219604
Drug: DiphenhydrAMINE Injectable Solution
Normalized name: diphenhydramine Injectable Solution
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of diphenhydramine 50 mg.
Study: NCT05109234
Drug: Brivaracetam Film-coated tablet
Normalized name: brivaracetam
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses.
Study: NCT05109234
Drug: Brivaracetam oral solution
Normalized name: brivaracetam Oral Solution
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses.
Study: NCT00443222
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06671405
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Period 2 (itraconazole administration only).~* Period 3 (AZD0780 + itraconazole administration).
Study: NCT06671405
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Period 2 (carbamazepine administration only).~* Period 3 (AZD0780 + carbamazepine administration only).
Study: NCT06671405
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Period 1 (midazolam administration only).~* Period 3 (AZD0780 + midazolam administration).
Study: NCT05600998
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks
Study: NCT06796907
Drug: Anticancer therapy 3
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticancer therapy 3 will be administered IV.
Study: NCT06593834
Drug: BAT
Normalized name: RibaTab
DrugBank: Equine Botulinum Neurotoxin E Immune FAB2 (DB13897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAT
Study: NCT04262193
Drug: Suvorexant
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In each group, the participant will take 1 tablet (placebo or 20mg) 30 minutes before bedtime.
Study: NCT04262193
Drug: Suvorexant Placebo
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suvorexant Placebo
Study: NCT06607796
Drug: Toluenesulfonamide (PTS) Intratumoral Injection
Normalized name: o-toluenesulfonamide
DrugBank: Toluene (DB11558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intratumoral injection of toluenesulfonamide(PTS) to oligo lesions
Study: NCT05942573
Drug: Serplulimab+Paclitaxel+Apatinib
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immunotherapy+chemotherapy
Study: NCT05942573
Drug: Paclitaxel±Ramucirumab
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: chemotherapy±Targeted therapy
Study: NCT05023941
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start orally take acetazolamide 125mg twice daily, 2 days before entering the hypoxic chamber. Subjects will enter the hypoxic room at 9am on the third day. At that time, the subject should have taken the drug 5 times.
Study: NCT05076877
Drug: Lazertinib
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib tablets will be administered orally, alone or in combination with probe substrates.
Study: NCT05076877
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (cytochrome P450 3A4 \[CYP3A4\] substrate) will be administered orally as a syrup as a part of probe substrates.
Study: NCT05076877
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (organic cation transporter 1 \[OCT1\] substrate) will be administered orally as a syrup as a part of probe substrates.
Study: NCT06730750
Drug: BMS-986490
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days.
Study: NCT06730750
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days.
Study: NCT06763146
Drug: Finerenone (Kerendia, BAY948862)
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Retrospective cohort analysis using the investigator or a delegate at the study site collects secondary/historic data of finerenone usage (patient demographic and clinical characteristics, diagnosis-related, treatment-related, and laboratory data) from clinic specific medical records.
Study: NCT06762054
Drug: Continue DTG-based antiretroviral therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will continue on DTG-based ART after enrollment for up to 12 months
Study: NCT06490081
Drug: Trilaciclib
Normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During concurrent chemoradiotherapy in limited-stage small cell lung cancer, Trilaciclib is administered prophylactically before the first cycle of chemotherapy
Study: NCT06437509
Drug: BL-B01D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06437509
Drug: PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT05468619
Drug: Valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valacyclovir is a L-valyl ester of acyclovir.
Study: NCT05655689
Drug: Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution
Normalized name: moxifloxacin ophthalmic 0.5% ophthalmic solution
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the observational study, patients treated with topical antibiotic moxifloxacin 0.5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Study: NCT05655689
Drug: Ceftazidime 5% + vancomycin 5%
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the observational study, patients treated with topical fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Study: NCT05655689
Drug: Natamycin 5% Oph Susp
Normalized name: NATAMYCIN 5% OPH SUSP
DrugBank: Natamycin (DB00826)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the observational study, patients treated with the topical natamycin 5% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Study: NCT05655689
Drug: Voriconazole 1%
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the observational study, patients treated with voriconazole 1% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Study: NCT05655689
Drug: Natamycin 5% + voriconazole 1%
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the observational study, patients treated with the topical natamycin 5% and voriconazole 1% antifungals eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Study: NCT05655689
Drug: Natamycin 5%+ ceftazidime 5% + vancomycin 5%
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the observational study, patients treated with the topical natamycin 5% and antifungal and the fortified antibiotic ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Study: NCT05655689
Drug: Voriconazole 1% + ceftazidime 5% + vancomycin 5%
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the observational study, patients treated with the topical voriconazole 1% antifungal and the fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Study: NCT05041803
Drug: CTP-543
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Twice daily dosing
Study: NCT05201326
Drug: Bevacizumab，Irinotecan and Re-radiotherapy
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients with recurrent glioblastoma will accept irinotecan and bevacizumab combined with re-radiotherapy .
Study: NCT05593653
Drug: Suvorexant
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg taken at bedtime for 4 weeks
Study: NCT06136455
Drug: Listerine Clinical Solutions Teeth Strength
Normalized name: SODIUM FLUORIDE 0.1 mg in 1 mL ORAL MOUTHWASH [Listerine Clinical Solutions Teeth Strength Alpine Mint]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Clinical Solutions Teeth Strength mouthwash.
Study: NCT06136455
Drug: Colgate Cavity Protection Toothpaste
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will brush for 1 timed minute with Colgate Cavity Protection toothpaste.
Study: NCT06765317
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1D8 2.5 mg iv; C1D15 10 mg iv; C2D1-onwards: 30 mg iv, every 3 weeks
Study: NCT06765317
Drug: Polatuzumab
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.8 mg/kg iv C1D1 onwards, every 3 weeks
Study: NCT06501807
Drug: Biologic treatments available in Chronic Rhinosinusitis with Nasal Polyps (dupilumab, mepolizumab and benralizumab according to their marketing approval).
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks).
Study: NCT06765317
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 iv D1
Study: NCT06765317
Drug: Obinutuzumab:
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000 mg iv C1D1 (7 days prior to glofitamab administration) single dose
Study: NCT05118620
Drug: Active bupivacaine 0.375% PENG block
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A PENG block with bupivacaine 0.375% and epinephrine will be administered using ultrasound-guidance
Study: NCT06161714
Drug: Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml
Normalized name: ARTICAINE 4%/EPI 1:100000 INJ CART 1.7ML
DrugBank: Articaine (DB09009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4% articaine with 1:100,000 epinephrine buccal infiltration